Theseus Pharmaceuticals Reports Initial Dose Escalation Data

-- THE-630 demonstrates encouraging safety profile through Cohort 6 , supportive of continued dose escalation --
-- Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for both... | May 25, 2023

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , United States , Philadelphia , Pennsylvania , Josh Rappaport , Christen Baglaneas , Tim Clackson , Suzanne George , David Kerstein , Clinical Development Plan , Corporate Communications Investor Relations , Dana Farber Cancer Institute , Theseus Pharmaceuticals , Exchange Commission , Theseus Pharmaceuticals Inc , Sarcoma Center , Nasdaq , Predictive Resistance Assay , Chief Executive Officer , Associate Division Chief , Chief Medical Officer , Trial Background , Clinical Development , Theseu Form , Quarterly Reports , Corporate Communications , Nc Stock Exchange , News , Information , Press Release , Emonstrates , Ncouraging , Safety , Profile , Through , Cohort , , Supportive , F , Ontinued , Nose , Escalation , Reductions , Bserved , N , Ctdna , Allele , Fractions , Or Thrx Us88369m1018 ,